Market By Product, Application, Technology, End-user And Geography | Forecast 2019-2028
A Triton Market Research report on the molecular point of care diagnostics market in the Asia-Pacific region, depicts that the industry will grow at a CAGR of 14.48% in the forecasted period 2019-2028.
We provide additional customization based on your specific requirements. Request For Customization
The countries studied in the Asia-Pacific molecular point of care diagnostics market are:
•          South Korea
•          China
•          ASEAN countries
•          Japan
•          India
•          Australia & New Zealand
•          Rest of APAC countries
In the Asia-Pacific region, the adoption of molecular point of care diagnostics is affected by three factors, namely awareness, availability and affordability. Therefore, regulatory authorities, diagnostic companies, pharmaceutical industry & service providers are trying to collaborate and offer an international platform to facilitate easy access to precision medicine technologies.
Moreover, the regional market is likely to experience rapid growth over the forthcoming years owing to the surge in healthcare awareness and a gradually steadying economy. Thus, there is increased affordability and accessibility of healthcare facilities. The adoption rate can also be considerably impacted by the advent of cost-efficient generic products by regional vendors. All these factors are responsible for the projected growth of the molecular point of care diagnostics market.
The market in China is witnessing growth due to various government initiatives launched to make precision medicine a well-accepted approach in the healthcare system, thereby driving the growth of the molecular diagnostics point of care market. Moreover, the rising aging population in the country has led to an increased occurrence of chronic disorders like diabetes, heart disease and cancer, which is pushing the demand for immediate reforms to enhance the healthcare services. Also, the growing cases of infectious disease in China have fuelled the need for the development of point of care diagnosis in order to ensure accurate detection.
Abbott Laboratories is a company that is involved in the development, manufacturing and marketing of a broad line of healthcare products. The company provides a wide portfolio, including pediatric & adult nutritional products, diagnostic systems, medical devices, neuromodulation devices and generic pharmaceuticals. It offers its products through consumers, retailers, wholesalers, health care facilities, third-party distributors, blood banks, government agencies, commercial laboratories and clinics. It has a business presence in different regions, including Asia-Pacific.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1.  INCREASED GERIATRIC POPULATION REQUIRES MORE DIAGNOSTIC SERVICES
2.2.2.  OPPORTUNITIES FROM EMERGING COUNTRIES FOR THE MARKET
2.2.3.  HYBRIDIZATION OF AVAILABLE TECHNOLOGIES IS A PROMISING TREND
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1.  THREAT OF NEW ENTRANTS
2.3.2.  THREAT OF SUBSTITUTE
2.3.3.  BARGAINING POWER OF SUPPLIERS
2.3.4.  BARGAINING POWER OF BUYERS
2.3.5.  THREAT OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. REGULATORY FRAMEWORK
2.6.1.  CHINA
2.6.2.  JAPAN
2.7. MARKET DRIVERS
2.7.1.  DEMAND FOR DIAGNOSING PRESENCE OF SARS COV-2
2.7.2.  INCREASING DEMAND FOR NON-INVASIVE DIAGNOSIS
2.7.3.  RISE IN THE NUMBER OF DISEASES
2.8. MARKET RESTRAINTS
2.8.1.  HIGH CAPITAL REQUIREMENT
2.9. MARKET OPPORTUNITIES
2.9.1.  SPENDING ON RESEARCH & DEVELOPMENT
2.9.2.  INNOVATIONS IN THE MARKET
2.10. MARKET CHALLENGES
2.10.1.LACK OF HIGH COMPLEXITY TESTING CENTERS
3. ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK – BY PRODUCT
3.1. ASSAYS
3.2. INSTRUMENTS
3.3. SOFTWARE
4. ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY APPLICATION
4.1. INFECTIOUS DISEASE
4.1.1.  RESPIRATORY
4.1.2.  HOSPITAL-ACQUIRED INFECTIONS
4.1.3.  SEXUALLY-TRANSMITTED INFECTIONS
4.1.4.  GASTROINTESTINAL INFECTIONS
4.2. ONCOLOGY
4.3. PRENATAL
4.4. OTHERS
5. ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY TECHNOLOGY
5.1. POLYMERASE CHAIN REACTION
5.1.1.  REAL-TIME PCR (Q-PCR)
5.1.2.  DIGITAL PCR (D-PCR)
5.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
5.3. OTHER
6. ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY END-USER
6.1. HOSPITAL
6.2. CLINICS
6.3. DIAGNOSTIC CENTERS
6.4. OTHERS
7. ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET – REGIONAL OUTLOOK
7.1. CHINA
7.2. JAPAN
7.3. INDIA
7.4. SOUTH KOREA
7.5. ASEAN COUNTRIES
7.6. AUSTRALIA & NEW ZEALAND
7.7. REST OF ASIA-PACIFIC
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT
8.2. ABACUS DIAGNOSTICA
8.3. BIOMERIEUX SA
8.4. BIOCARTIS
8.5. DANAHER
8.6. DIASORIN SPA
8.7. BIO-RAD LABORATORIES INC
8.8. F HOFFMANN-LA ROCHE LTD
8.9. LUMINEX CORPORATION
8.10. HOLOGIC INC
8.11. MESA BIOTECH
8.12. SPARTAN BIOSCIENCES INC
8.13. QUANTUMDX GROUP LTD
8.14. QUIDEL CORPORATION
8.15. QIAGEN
9. METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY
TABLE 1: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 5: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: COST COMPARISON BETWEEN LABORATORY, IMMUNOASSAY AND MOLECULAR POC DIAGNOSTIC TESTS
FIGURE 3: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)
FIGURE 4: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)
FIGURE 5: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)
FIGURE 6: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL-ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY-TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTROINTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL-TIME PCR (Q-PCR), 2019-2028 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR (D-PCR), 2019-2028 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)
FIGURE 19: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL, 2019-2028 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTERS, 2019-2028 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2018 & 2028 (IN %)
FIGURE 24: CHINA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 25: JAPAN MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 26: INDIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 27: SOUTH KOREA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 28: ASEAN COUNTRIES MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 29: AUSTRALIA & NEW ZEALAND MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 30: REST OF ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)